News Releases

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies. In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of novel bispecific antibody-based gamma
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced
LAVA Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the annual
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma Initial clinical data for LAVA-1207, a Phase 1/2a
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicities Preliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable patients at week 8 and PSA levels stabilizing or
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer,
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced
LAVA Therapeutics Announces Appointment of New Directors to the Board
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific